The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.
 
Mark Glaire
No Relationships to Disclose
 
Enric Domingo
No Relationships to Disclose
 
George Nicholson
No Relationships to Disclose
 
Marco Novelli
Employment - Room 4
Stock and Other Ownership Interests - Room 4
Patents, Royalties, Other Intellectual Property - Room 4
 
Kay Lawson
No Relationships to Disclose
 
Dahmane Oukrif
No Relationships to Disclose
 
Wanja Kidal
No Relationships to Disclose
 
Havard Emil Danielsen
No Relationships to Disclose
 
Rachel Kerr
No Relationships to Disclose
 
David J. Kerr
Employment - Celleron Therapeutics
Leadership - Oxford cancer biomarkers
Stock and Other Ownership Interests - Celleron Therapeutics; Oxford cancer biomarkers; OxOnc
Honoraria - Medscape
Consulting or Advisory Role - Amgen; Merck Serono; Merck Sharp & Dohme
Speakers' Bureau - Novartis
Research Funding - Fresenius Kabi; Roche
Patents, Royalties, Other Intellectual Property - patents pending on two biomarker tests developed for Oxford Cancer Biomarkers
 
Ian Tomlinson
No Relationships to Disclose
 
David N. Church
No Relationships to Disclose